Christopher D. Alafi, Director, 10% Owner at Intra-Cellular Therapies, Inc. (ITCI), bought 960,211 shares at $11.00 ($9.8M) on 2019-09-10, disclosed to the SEC on 2019-09-11.
Open-market purchase of $9.8M ITCI by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.98 | 3,549 | $32K | 0.3% |
| 2 | $9.59 | 155,116 | $1.5M | 15.1% |
| 3 | $9.59 | 155,116 | $1.5M | 15.1% |
| 4 | $10.58 | 320,095 | $3.4M | 34.4% |
| 5 | $10.58 | 320,095 | $3.4M | 34.4% |
| 6 | $11.00 | 6,240 |
| $69K |
| 0.7% |
| Total | $10.26 avg | 960,211 | $9.8M | 100% |
| Filing → |
| ITCI | BUY | 2020-09-14 | $1.5M | — | Filing → |
| ITCI | BUY | 2020-09-11 | $590K | — | Filing → |
| ITCI | BUY | 2019-09-04 | $1.1M | — | Filing → |